Veloxis Pharmaceuticals A/S (VELOX.CO) Company Profile | Reuters.com
Edition:
United States

Profile: Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.10DKK
10:59am EDT
Change (% chg)

kr.-0.01 (-0.90%)
Prev Close
kr.1.11
Open
kr.1.11
Day's High
kr.1.11
Day's Low
kr.1.08
Volume
3,681,841
Avg. Vol
1,923,819
52-wk High
kr.2.10
52-wk Low
kr.0.83

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based company active in the biotechnology and pharmaceutical industry. It is primarily focused on the development of its transplant immunosuppression product candidate, LCP-Tacro. LCP-Tacro is being developed as a once-daily dosage version of tacrolimus for the treatment of kidney and liver transplant patients. Additionally, the Company develops pharmaceuticals in the cardiovascular therapeutic area, such as LCP-FenoChol (Fenoglide) for the treatment of dyslipidemia and hypercholesterolemia, and AtorFen, a fixed dose combination tablet of fenofibrate and atorvastatin. The Company utilizes its MeltDose technology platform for enhancing the bioavailability of compounds with low water solubility.

Company Address

Veloxis Pharmaceuticals A/S

2. Sal, Agern Alle 24
HOERSHOLM     2970

Company Web Links